Organigram (OGI) Q3 2026 earnings review
Sanity Acquisition Drives Record Growth, But Cash Burn and U.S. Retreat Raise Questions
Organigram's Q3 2026 printed massive headline numbers: Net Revenue jumped 49% YoY to $105.8M and Adjusted EBITDA surged 136% to a record $13.4M. The catalyst was the newly acquired Sanity Group, which injected ~C$40M into the top line. However, investors should look closely at the staggering $105.5M Net Income figure—it is an optical illusion created by a $105.8M non-cash fair value gain on BAT preferred shares. Operationally, the quarter exposed severe working capital constraints that flipped Free Cash Flow to negative $3.9M, forcing management to downgrade full-year FCF guidance to negative. Additionally, the company is effectively waving the white flag on its U.S. Hemp strategy due to unworkable federal regulations.
🐂 Bull Case
The Sanity Group acquisition immediately validated Organigram's European expansion thesis, contributing €25M (C$40M) in its first partial quarter and driving international and medical segments to unprecedented levels.
Adjusted gross margin improved to 37% (from 34% a year ago). Despite absorbing the Sanity integration, operational efficiencies in Canada and a richer product mix are sustaining robust profitability at the unit level.
🐻 Bear Case
Management had to abandon their 'positive FCF for FY26' guidance, revising it to 'modestly negative.' Increased scale required massive working capital investments, dragging Q3 operating cash flow to negative $4.3M.
Due to changes in the U.S. Farm Bill (Section 781), Organigram is pausing its U.S. hemp THC business. The company already took a $5.8M impairment in Q2 and wrote its Open Book Extracts (OBX) investment down to zero in Q3.
⚖️ Verdict: ⚪
Neutral. The Sanity Group acquisition transformed the P&L and provides a massive revenue runway in Europe. However, the cash burn, the total collapse of the U.S. hemp thesis, and low-quality reported Net Income demand caution.
Key Themes
Sanity Group Cements European Leadership
Accelerating. The €107.3M acquisition of Sanity Group closed in April and radically altered Organigram's geographic mix. Sanity contributed C$40M in just over two months, catapulting European net revenue to $39.9M for the quarter (up from $5.6M in 25Q3). This instantly transitions Organigram from a domestic operator with a side export business into a true multi-national cannabis platform.
Working Capital Reverses Free Cash Flow Trajectory
Reversing. In prior quarters, management championed a pivot to sustained positive Free Cash Flow. This quarter broke that narrative. Operating cash flow fell to negative $4.3M (compared to positive $14.6M in 25Q3). Management blamed working capital requirements associated with increased scale and the Sanity integration, forcing a downgrade to full-year FCF guidance.
U.S. Hemp Strategy Goes Up in Smoke
Reversing. The U.S. Continuing Appropriations and Extensions Act of 2026 effectively outlawed hemp-derived THC products. Organigram is pausing its U.S. hemp business entirely. Following a $5.8M impairment on its Collective Project acquisition in Q2, the company wrote down its investment in Open Book Extracts (OBX) to $0 this quarter (a $3.5M hit). A major growth vector has been eliminated by regulatory stroke.
Net Income is an Optical Illusion
Stable. The headline $105.5M Net Income figure is incredibly deceptive. Operating income was a modest $5.3M. The massive net income was generated by a $105.8M non-cash fair value gain on preferred shares issued to BAT. The gain occurred because the timeline for BAT reaching its 49% ownership cap shortened, reducing future accretion liability. Investors must completely ignore the bottom-line EPS this quarter.
Canadian Core Remains Highly Profitable
Stable. Amid the international noise, the domestic Canadian business performed well. Recreational net revenue ticked up to $61.8M (from $59.9M YoY). Adjusted gross margin held strong at 37%, proving that cultivation efficiencies (like seed-based breeding and proprietary powdery mildew screening) are defending profitability against brutal domestic pricing pressure.
Other KPIs
Improving. SG&A expenses rose 34% YoY to $32.7M due to the Sanity Group consolidation and higher marketing investments. However, because revenue grew 49%, SG&A as a percentage of net revenue actually dropped 400 basis points from 35% in 25Q3, demonstrating solid operating leverage.
Slightly decelerating from the $18.2M gain recognized in 25Q3. The company is extracting heavy non-cash IFRS gains from its cultivation optimization, but the actual realized fair value on inventory sold resulted in a $14.4M charge, largely neutralizing the P&L impact.
Guidance
Accelerating. The company upgraded its full-year revenue outlook from 'exceeding $300 million' to 'exceeding $350 million', entirely due to the successful closing and rapid integration of the Sanity Group acquisition.
Reversing. Management officially downgraded their FY26 target from 'generate positive free cash flow' to 'modestly negative free cash flow.' While they expect Q4 to be positive, the massive working capital requirements of integrating Europe proved too much for the annual metric.
Key Questions
Working Capital Normalization
You attributed the Q3 cash burn to working capital needs from increased scale. Can you quantify exactly how much of this was a one-time integration build for Sanity versus an ongoing structural requirement for the larger European footprint?
EU-GMP Certification Timeline
You submitted requested documentation for the EU-GMP certification in April 2026. Given the continued delays and lack of a hard timeline, are there alternative contingency plans for European supply if the Moncton facility certification stalls indefinitely?
Capital Reallocation from U.S. Hemp
With the effective abandonment of the U.S. hemp strategy, how much capital and management bandwidth is being freed up, and will this strictly be redirected toward the European footprint via the Jupiter Pool?